Wellpep Co. Ltd. has divulged peptidomimetic compounds reported to be useful for the treatment of atopic dermatitis.

Latvian Institute of Organic Synthesis has identified selenium compounds acting as estrogen receptor α (ER-α; ESR1) modulators reported to be useful for the treatment of cancer.

Purdue Research Foundation has synthesized proteolysis targeting chimeras (PROTACs) comprising a E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and 2 (PTPN2; TCPTP) dual targeting moiety reported to be useful for the treatment of cancer, type 2 diabetes and obesity.

Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new glucagon-like peptide 1 receptor (GLP-1R) agonists described as potentially useful for the treatment of diabetes, obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

Recent patents from Opna Bio AG detail new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney and Alzheimer’s disease.

A Contineum Therapeutics Inc. patent describes a crystalline form of lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of brain cancer, glioblastoma, idiopathic pulmonary fibrosis, inflammatory disorders, multiple sclerosis, neurodegeneration, neuropathic pain and scleroderma, among others.

Work at the Korea Institute of Radiological and Medical Sciences and Korea Research Institute of Chemical Technology has led to the identification of new poly(ADP-ribose) polymerase tankyrase (TNKS) inhibitors potentially useful for the treatment of cancer.

Eli Lilly & Co. has patented new fluorine-radiolabeled compounds targeting microtubule-associated protein tau (PHF-tau; MAPT).

Korean Research Institute of Bioscience and Biotechnology and Korea Research Institute of Chemical Technology have jointly developed molecular glue degraders acting as zinc finger protein Helios (IKZF2) degradation inducers. They are described as potentially useful for the treatment of cancer.